Eisai and Biogen Alzheimer's drug lecanemab receives approva

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.

Related Keywords

United States , Tokyo , Japan , Montana , Americans , Alvaro Pascual Leone , James Galvin , Jack Hanna , Ivan Cheung , Adam Cairns , Joanne Pike , University Of Miami Health System , Alzheimer Association , Harvard Medical School , Drug Administration On , Linus Health , Centers For Medicare , Medicaid Services , Drug Administration , Japan Based Eisai , Miami Health System ,